Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
NCT01732861 · View on ClinicalTrials.gov ↗
Study Summary
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and lenalidomide in subjects with Chronic Lymphocytic Leukemia (CLL).
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG CC-292
Study Locations (11)
Other
- Universitatsklinik fur Innere Medizin — Innsbruck
- AKh Linz — Linz
- Universitatsklinik der PMU — Salzburg
- Allgemeines Krankenhaus Wien — Vienna
- Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie — Vienna
Alabama
- Clearview Cancer Institute Oncology Specialties, P.C — Huntsville
Indiana
- Horizon Oncology Center — Lafayette
New Jersey
- Hackensack University Medical Center — Hackensack
New York
- Mount Sinai School of Medicine — New York
Tennessee
- The West Clinic — Memphis
Texas
- MD Anderson Cancer Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-12-28 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732861
The ClinicalTrials.gov registry entry for NCT01732861 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 73 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Leukemia Lymphocytic Chronic B-Cell appearing as the primary indexed condition, and to 2 interventions — of which Lenalidomide is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01732861 reports 11 study locations spanning 7 distinct geographic areas — top geographies include Other, Alabama, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01732861 about?
NCT01732861 is a clinical study titled "Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma". This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 an...
What is the current status of trial NCT01732861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-12-28. Estimated completion is 2019-01-23.
What conditions does trial NCT01732861 study?
This clinical trial studies the following conditions: Leukemia Lymphocytic Chronic B-Cell. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01732861?
The interventions under investigation include: Lenalidomide (DRUG), CC-292 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01732861?
This trial is sponsored by Celgene, which has 73 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01732861 being conducted?
This trial has 11 study locations across Alabama, Indiana, New Jersey, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.